NCT00796263 - Antiretroviral Therapy for Acute and Chronic HIV Infection | Biotech Hunter

Enrollment

900

Participants

Timeline

Start Date

May 13, 2009

Primary Completion Date

June 30, 2033

Study Completion Date

June 30, 2033

Conditions

Acute HIV InfectionChronic HIV Infection

Interventions

DRUG

HAART

"1 (lamivudine) or 2 (lamivudine + abacavir) nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications once daily~plus~dolutegravir(DTG) 50 mg orally once daily"

Trial Locations (1)

10330

RECRUITING

Institute of HIV Research and Innovation, Bangkok